Abstract:The need to develop new antipsychotics that have fewer motor adverse effects and offer better treatment of negative symptoms has led to a new generation of drugs. Most of these drugs undergo extensive first-pass metabolism and are cleared almost exclusively by metabolism, except for amisulpride whose clearance is largely due to urinary excretion. Risperidone has metabolic routes in common with ziprasidone but shows differences in regard to other main pathways: the benzisoxazole moiety of risperidone is oxidised by cytochrome P450 (CYP) 2D6 to the active 9-hydroxyrisperidone, whereas the benzisothiazole of ziprasidone is primarily oxidised by CYP3A4, yielding sulfoxide and sulfone derivatives with low affinity for target receptors in vitro. Olanzapine, quetiapine and zotepine also have some common metabolic features. However, for the thienobenzodiazepine olanzapine a main metabolic route is direct conjugation at the benzodiazepine nucleus, whereas for the dibenzothiazepine quetiapine and the dibenzothiepine zotepine it is CYP3A4-mediated oxidation, leading to sulfoxidation, hydroxylation and dealkylation for quetiapine, but N-demethylation to the active nor-derivative for zotepine. Although the promising benzisoxazole (iloperidone) and benzisothiazole (perospirone) antipsychotics share some metabolic routes with the structurally related available drugs, they too have pharmacologically relevant compound-specific pathways. For some of the new antipsychotics we know the isoenzymes involved in their main metabolic pathways and the endogenous and exogenous factors that, by affecting enzyme activity, can potentially modify steady-state concentrations of the parent drug or its metabolite(s), but we know very little about others (e.g. amisulpride isomers, nemonapride). For yet others, information is scarce about the activity of the main metabolites and whether and how these contribute to the effect of the parent drug. Aging reduces the clearance of most antipsychotics, except amisulpride (which requires further evaluation) and ziprasidone. Liver impairment has little or no effect on the pharmacokinetics of olanzapine, quetiapine, risperidone (and 9-hydroxy-risperidone) and ziprasidone, but information is lacking for amisulpride. Renal impairment significantly reduces the clearance and prolongs the elimination half-life of amisulpride and risperidone. Again, studies are still not available for some drugs (zotepine) and have focused on the parent drug for others (olanzapine, quetiapine, ziprasidone) despite the fact that renal impairment would be expected to lower the clearance of more polar metabolites. Addressing these issues may assist clinicians in the design of safe and effective regimens for this group of drugs, and in selecting the best agent for each specific population.

Theoretical Elucidation of the Metabolic Mechanisms of Phenothiazine Neuroleptic Chlorpromazine Catalyzed by Cytochrome P450 Isoenzyme 1A2

Theoretical study on the metabolic mechanisms of levmepromazine by cytochrome P450

Computational Investigation of the Bisphenolic Drug Metabolism by Cytochrome P450: What Factors Favor Intramolecular Phenol Coupling

Using Physical Organic Chemistry Knowledge to Predict Unusual Metabolites of Synthetic Phenolic Antioxidants by Cytochrome P450.

Emerging Metabolic Profiles of Sulfonamide Antibiotics by Cytochromes P450: A Computational-Experimental Synergy Study on Emerging Pollutants.

Computational Biotransformation Profile of Paracetamol Catalyzed by Cytochrome P450.

In Silico Simulation of Cytochrome P450-Mediated Metabolism of Aromatic Amines: A Case Study of N-Hydroxylation

Electrochemical Synthesis of the In Human S-oxide Metabolites of Phenothiazine-Containing Antipsychotic Medications

Detoxification of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Cytochrome P450 Enzymes: A Theoretical Investigation.

Biotransformation of post-clozapine antipsychotics: pharmacological implications

Electrochemical Synthesis of the in human S-oxide metabolites of phenothiazine containing Anti-Psychotic Medications

Regioselective Oxidation of Heterocyclic Aromatic Hydrocarbons Catalyzed by Cytochrome P450: A Case Study of Carbazole.

Metabolic profiling of lysophosphatidylcholines in chlorpromazine hydrochloride- and N-acetyl-p-amino-phenoltriptolide-induced liver injured rats based on ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry

Theoretical study on the N-demethylation mechanism of theobromine catalyzed by P450 isoenzyme 1A2

Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450

DFT investigation on the metabolic mechanisms of theophylline by cytochrome P450 monooxygenase

On the mechanisms of phenothiazine-induced mitochondrial permeability transition: Thiol oxidation, strict Ca2+ dependence, and cyt c release

Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2

Interindividual Variation In Relative Cyp1a2/3a4 Phenotype Influences Susceptibility Of Clozapine Oxidation To Cytochrome P450-Specific Inhibition In Human Hepatic Microsomes

The pyrethroids metabolite 3-phenoxybenzoic acid induces dopaminergic degeneration

Synthesis, Theoretical Gaussian Quantum Chemical Calculations, and Spectroscopic Elucidation of N‐(4‐bromophenyl)‐10H‐phenothiazine‐10‐carboxamide